Search

Your search keyword '"Scott, Kenneth L"' showing total 85 results

Search Constraints

Start Over You searched for: Author "Scott, Kenneth L" Remove constraint Author: "Scott, Kenneth L" Database Unpaywall Remove constraint Database: Unpaywall
85 results on '"Scott, Kenneth L"'

Search Results

2. Supplementary Tables from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

3. Supplementary information from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

4. Tables S1-S6 from Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer

5. Data from Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer

6. Figures S1-S4 from Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer

7. Figures S1-S4 from Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer

8. Supplementary Figures from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

9. Data from Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer

10. Data from Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations

11. Supplementary Tables S1-S5 from Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations

12. Data from Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations

13. Supplementary Tables S1-S5 from Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations

14. Supplementary Figures S1-S2 from Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations

15. Supplementary Figures S1-S2 from Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations

17. A functional genomic approach to actionable gene fusions for precision oncology

18. POT1 Regulates Proliferation and Confers Sexual Dimorphism in Glioma

20. Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression

21. Author response: Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression

22. PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis

24. PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinoma

26. Bacteria-to-Human Protein Networks Reveal Origins of Endogenous DNA Damage

29. Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2

30. RNA editing derived epitopes function as cancer antigens to elicit immune responses

32. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer

33. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network

34. Bacteria-to-human protein networks reveal origins of endogenous DNA damage

36. A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer

37. A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis

38. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer

39. Systematic Functional Annotation of Somatic Mutations in Cancer

40. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network

42. Daam2 driven degradation of VHL promotes gliomagenesis

43. Author response: Daam2 driven degradation of VHL promotes gliomagenesis

44. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

46. Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer

47. A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations

48. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

50. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers

Catalog

Books, media, physical & digital resources